AstraZeneca has been selling Nexium in Canada for 13 years. It is prescribed to treat ulcers, gastroesophageal reflux disease (GERD) and related diseases. The active
Last August, China’s State Intellectual Property Office (SIPO) invalidated the core patent for Gilead Sciences‘ flagship drug Viread (as was reported by IPR Daily and a
What do cooking and chemistry have in common? Apparently, the former provides great analogies to explain the latter. Apotex has recently applied for judicial review
My 10 week internship at Actavis’ Canadian arm (formerly known as Cobalt), through Osgoode’s IP Intensive Program coincided with a very exciting time for the
The outline of CETA has arrived – but its full text is still in transit. On what we know of the intellectual property aspects of
At long last, the Canadian Federal Government and the European Commission announced in October that a political agreement has been reached regarding the much anticipated
